RHEPB Swings to Profit on SunLink Merger, Pharmacy Growth

TL;DR

**RHEPB's SunLink merger and new pharmacy business are a game-changer, driving a massive profit swing and making it a speculative buy for growth-hungry investors.**

AI Summary

Regional Health Properties, Inc. (RHEPB) reported a significant turnaround, achieving a net income of $3.382 million for the three months ended September 30, 2025, compared to a net loss of $982,000 in the same period of 2024. For the nine months ended September 30, 2025, net income was $671,000, a substantial improvement from a net loss of $2.650 million in 2024. Total revenues surged to $15.138 million for the three-month period, up from $4.225 million year-over-year, primarily driven by a new Pharmacy Services segment contributing $4.004 million and a substantial increase in Patient Care revenues to $9.831 million from $2.585 million. The company completed a merger with SunLink Health Systems, Inc. on August 14, 2025, which included a gain on bargain purchase of $5.311 million. Despite increased costs and expenses, including patient care expense rising to $8.639 million from $2.179 million, the merger and new revenue streams propelled profitability. The company's common stock and Series A Preferred Stock were delisted from NYSE American on June 11, 2025, and now trade on the OTCQB under symbols RHEP and RHEPA, respectively, indicating a shift in market accessibility and potentially liquidity.

Why It Matters

This filing reveals a critical turning point for Regional Health Properties, Inc., as the SunLink merger and the launch of a Pharmacy Services segment have dramatically improved its financial health, moving from significant losses to profitability. For investors, this signals potential for renewed growth and a more diversified revenue base beyond traditional real estate and healthcare services, which could attract new capital. Employees of both RHEPB and the acquired SunLink entities may see increased job security and opportunities within a larger, more stable organization. Customers could benefit from expanded pharmacy services and potentially improved healthcare offerings. In the competitive landscape, RHEPB's strategic acquisition and diversification could position it more strongly against other healthcare REITs and service providers, though the delisting to OTCQB might limit broader institutional investor interest.

Risk Assessment

Risk Level: medium — While the company reported a net income of $3.382 million for the quarter, a significant portion is due to a non-recurring $5.311 million gain on bargain purchase from the SunLink merger. Operating activities still resulted in a net cash outflow of $994,000 for the nine months ended September 30, 2025, indicating ongoing operational challenges despite revenue growth. The delisting from NYSE American to OTCQB also suggests reduced liquidity and potentially higher volatility for its shares.

Analyst Insight

Investors should closely monitor RHEPB's future operational cash flow and the sustainability of its new revenue streams, particularly the Pharmacy Services segment, independent of one-time gains. Consider this a speculative investment given the recent delisting and reliance on acquisition-related gains for profitability, but the revenue growth warrants further investigation into its long-term strategy.

Financial Highlights

debt To Equity

N/A

revenue

$15.138M

operating Margin

N/A

total Assets

$72,150,000

total Debt

$48,571,000

net Income

$3.382M

eps

$1.17

gross Margin

N/A

cash Position

$994,000

revenue Growth

+258.3%

Revenue Breakdown

Key Numbers

• $3.382M — Net Income (Q3 2025) (Significant turnaround from $982K net loss in Q3 2024)
• $15.138M — Total Revenues (Q3 2025) (Increased from $4.225M in Q3 2024, driven by new segments)
• $5.311M — Gain on Bargain Purchase (One-time gain from SunLink merger, boosting net income)
• $4.004M — Pharmacy Revenues (Q3 2025) (New revenue stream contributing significantly to total revenues)
• $9.831M — Patient Care Revenues (Q3 2025) (Substantial increase from $2.585M in Q3 2024)
• $994K — Net Cash Used in Operating Activities (9M 2025) (Despite net income, operations still consume cash)
• 3,934,677 — Common Shares Outstanding (As of November 13, 2025, reflecting merger-related issuance)
• August 14, 2025 — SunLink Merger Date (Key event driving financial changes in the quarter)
• June 11, 2025 — NYSE American Delisting Date (Shifted trading to OTCQB for RHEP and RHEPA)
• $1.17 — Basic EPS (Q3 2025) (Positive EPS compared to ($0.52) in Q3 2024)

Key Players & Entities

• Regional Health Properties, Inc. (company) — Registrant and surviving corporation in merger
• SunLink Health Systems, Inc. (company) — Company merged into Regional Health Properties, Inc.
• NYSE American LLC (regulator) — Exchange that delisted RHEPB's common and preferred stock
• OTCQB (regulator) — Current trading market for RHEPB's common and preferred stock
• $3.382 million (dollar_amount) — Net Income for three months ended September 30, 2025
• $982,000 (dollar_amount) — Net Loss for three months ended September 30, 2024
• $5.311 million (dollar_amount) — Gain on bargain purchase from SunLink merger
• $15.138 million (dollar_amount) — Total revenues for three months ended September 30, 2025
• $4.004 million (dollar_amount) — Pharmacy revenues for three months ended September 30, 2025
• $994,000 (dollar_amount) — Net cash used in operating activities for nine months ended September 30, 2025

FAQ

Risk Factors

• Integration of SunLink Health Systems [high — financial]: The successful integration of SunLink Health Systems, Inc. is critical. Failure to realize anticipated synergies or manage integration challenges could negatively impact financial performance and operational efficiency. The company incurred a significant gain on bargain purchase of $5.311 million, indicating potential complexities in the acquisition accounting.
• Delisting from NYSE American [medium — market]: The delisting of common stock and Series A Preferred Stock from NYSE American to OTCQB may impact liquidity and investor perception. Trading on OTCQB could lead to reduced trading volume and potentially wider bid-ask spreads, affecting the ease with which investors can buy or sell shares.
• Increased Operating Expenses [medium — operational]: Patient care expenses rose significantly to $8.639 million in Q3 2025 from $2.179 million in Q3 2024. Managing these increased costs while maintaining profitability will be a key operational challenge.
• Healthcare Regulatory Environment [medium — regulatory]: The company operates in the highly regulated healthcare industry. Changes in healthcare laws, reimbursement policies, or compliance requirements could adversely affect operations and profitability. Specific details on regulatory compliance are not elaborated in the provided text.
• Cash Flow from Operations [medium — financial]: Despite reporting net income, the company used $994,000 in operating activities for the nine months ended September 30, 2025. Sustained negative operating cash flow could strain liquidity and require additional financing.

Industry Context

The healthcare services industry is characterized by significant regulatory oversight, evolving reimbursement models, and the ongoing consolidation of providers. Companies like Regional Health Properties, Inc. often operate in niche segments, such as patient care and specialized pharmacy services. The recent merger with SunLink Health Systems indicates a trend towards consolidation, aiming to achieve economies of scale and expand service offerings within this competitive landscape.

Regulatory Implications

Operating within the healthcare sector exposes Regional Health Properties, Inc. to a complex web of federal and state regulations, including those related to patient care, billing, and pharmacy operations. Changes in Medicare and Medicaid reimbursement rates, HIPAA compliance, and potential shifts in healthcare policy could materially impact the company's financial condition and operational strategies.

What Investors Should Do

1. Monitor integration progress of SunLink Health Systems.
2. Assess the impact of the OTCQB listing on liquidity and valuation.
3. Analyze the sustainability of increased patient care expenses.
4. Evaluate the contribution and scalability of the new Pharmacy Services segment.

Key Dates

• 2025-08-14: Completion of Merger with SunLink Health Systems, Inc. — This event significantly impacted the company's financial structure, leading to a substantial gain on bargain purchase and integration of new operations and revenues.
• 2025-06-11: Delisting from NYSE American — The company's common stock (RHEP) and Series A Preferred Stock (RHEPA) moved to OTCQB, potentially affecting liquidity and investor access.
• 2025-09-30: End of Third Quarter — Reporting period for the significant turnaround in net income and revenue growth, largely due to the SunLink merger.
• 2024-09-30: End of Third Quarter (Prior Year) — Comparison period showing a net loss of $982,000 and lower revenues of $4.225 million, highlighting the dramatic year-over-year improvement.

Glossary

Gain on Bargain Purchase

Occurs when an acquired company is purchased for less than the fair value of its identifiable net assets. This results in a one-time gain for the acquirer. (A significant $5.311 million gain from the SunLink merger boosted RHEPB's net income in the current period.)

OTC QB

A quotation service for over-the-counter (OTC) stocks, generally for companies that meet higher financial standards than those quoted on OTC Pink. (RHEPB's securities now trade on this market after being delisted from NYSE American.)

Patient Care Revenues

Revenue generated from providing healthcare services directly to patients. (This segment saw a substantial increase to $9.831 million in Q3 2025, a key driver of the company's improved financial performance.)

Pharmacy Services

Revenue generated from the operation of pharmacy services. (A new segment for RHEPB, contributing $4.004 million in Q3 2025, indicating diversification of revenue streams.)

Accumulated Deficit

The cumulative net losses of a company over its lifetime that have not been offset by net income. (RHEPB still carries a substantial accumulated deficit of ($84.774 million) as of September 30, 2025, despite recent profitability.)

Year-Over-Year Comparison

Regional Health Properties, Inc. has demonstrated a dramatic financial turnaround compared to the prior year. Total revenues for the three months ended September 30, 2025, surged to $15.138 million from $4.225 million in the same period of 2024, driven by the successful integration of SunLink Health Systems and the introduction of a new Pharmacy Services segment. This revenue growth, coupled with a significant one-time gain on bargain purchase from the merger, propelled net income to $3.382 million, a substantial improvement from a net loss of $982,000 in Q3 2024. While operating expenses, particularly patient care expenses, have also increased significantly, the overall financial picture shows a marked positive shift.

Filing Documents

• rhe-20250930.htm (10-Q) — 3714KB
• rhe-ex31_1.htm (EX-31.1) — 15KB
• rhe-ex31_2.htm (EX-31.2) — 15KB
• rhe-ex32_1.htm (EX-32.1) — 9KB
• rhe-ex32_2.htm (EX-32.2) — 9KB
• 0001193125-25-283236.txt ( ) — 16556KB
• rhe-20250930.xsd (EX-101.SCH) — 2019KB
• rhe-20250930_htm.xml (XML) — 3887KB

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 5 Consolidated Statements of Stockholders' (Deficit) Equity for the three and nine months ended September 30, 2025 and 2024 6 Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 7 Notes to Unaudited Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 32 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42 Part II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 45 Item 6. Exhibits 45

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES CONSOLIDATED B ALANCE SHEETS (Amounts in 000's) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Property and equipment, net $ 35,915 $ 33,489 Asset held for sale, net 10,372 10,334 Cash 994 582 Restricted cash 2,998 2,890 Accounts receivable, net of allowances of $ 880 and $ 141 7,715 3,362 Prepaid expenses and other 1,760 633 Inventory 1,435 — Notes receivable 369 369 Intangible assets 4,527 2,540 Right-of-use operating lease assets 2,494 2,154 Goodwill 1,585 1,585 Straight-line rent receivable 1,986 2,527 Total assets $ 72,150 $ 60,465 LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Senior debt, net $ 33,913 $ 34,829 Debt related to asset held for sale, net 7,925 8,121 Bonds, net 5,697 5,851 Other debt, net 1,043 919 Accounts payable 7,928 3,695 Accrued expenses 8,008 5,414 Operating lease obligation 2,773 2,472 Other liabilities 1,710 2,082 Total liabilities 68,997 63,384 Preferred stock, Series D, no par values, 1,408 shares authorized; 1,408 shares issued and outstanding at September 30, 2025; and 0 shares issued and 0 shares outstanding at December 31, 2024. 4,691 — Stockholders' (deficit) equity: Common stock and additional paid-in capital, no par value; 55,000 shares authorized; 3,946 shares issued and 3,935 shares outstanding at September 30, 2025; and 1,850 shares issued and 1,839 shares outstanding at December 31, 2024 67,234 63,173 Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A and Series B; shares issued and outstanding designated as follows: Preferred stock, Series A, no par value; 560 shares authorized, issued and outstanding at September 30, 2024 and December 31, 2023, with a redemption amount $ 426 at September 30, 2025 and December 31, 202

View Full Filing

View this 10-Q filing on SEC EDGAR